News Archive

March 2018

• Press Release Mar 22, 2018

  Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

  Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
• Press Release Mar 20, 2018

  Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

  Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline  Teams will explore the development…
• Press Release Mar 13, 2018

  AveXis Enters into Licensing Agreement with Genethon

  Includes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
• Ad-hoc Release Mar 12, 2018

  Novartis announces changes to the Executive Committee to support strategic priorities

  Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
• Ad-hoc Release Mar 12, 2018

  Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an

  Bertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
• Ad-hoc Release Mar 12, 2018

  Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques

  Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
• Press Release Mar 07, 2018

  Novartis expands alliance with Science 37 to advance virtual clinical trials program

  Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
• Press Release Mar 06, 2018

  Novartis' Xolair® recommended in new global chronic urticaria guideline

  Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
• Press Release Mar 02, 2018

  Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting

  Shareholders approve 21st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow  Dr. Joerg Reinhardt…
• Press Release Mar 02, 2018

  Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale

  Les actionnaires approuvent la 21e hausse consécutive du dividende, à CHF 2,80 (+2 %) par action au titre de l'exercice 2017, soit un rendement de 3,6 % et une distribution du free cash-…
• Press Release Mar 02, 2018

  Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats

  Aktionäre genehmigen für 2017 die 21. Dividendenerhöhung in Folge auf CHF 2,80 pro Aktie (+2%) - dies entspricht einer Rendite von 3,6% und einer Ausschüttungsquote von rund 67% des Free Cashflow…
• Press Release Mar 01, 2018

  Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

  Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis  Collaboration combines Novartis'…